Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 06/19/2015 - 04/22/2018

Target Audience

This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

Based on the wide spread failure rate of CNS clinical trials a renewed focus on early drug development is necessary. Novel study designs and technologies to enhance Phase I-II studies support and de-risk Proof of Concept trials, using a ‘go no-go’ strategy. The growing application of a Research Domain Criteria (NIMH initiative) approach to drug development and patient ‘diagnosis’, along with the prioritization of behavioral, biomarker, and other neurophysiological measures demonstrating engagement in neurocircuitry of relevance might be the ‘path forward’ to successful development of new therapies for our patients with brain disorders.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Faculty Information and Disclosures

Larry Ereshefsky, PharmD, BCPP, FCCP
Brett English, PharmD, PhD

View biographical information and disclosures

Learning Objectives

  1. Describe the current challenges in traditional drug development strategies and the need for novel approaches for new therapies of CNS disorders.
  2. Explain the bases for a shift to a Research Domain Criteria and how this approach can support neurocircuitry-based CNS drug development programs.
  3. Outline drug development plans for different novel psychotropics, which incorporate pre-clinical translational strategies and biomarker neurocircuitry assessments in healthy volunteers and in patients.

Continuing Education Credit and Disclosures

Activity Dates: 06/19/2015 - 04/22/2018
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-15-022-H04-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.0 contact hours (0.10CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-15-022-H04-P (1.0 contact hours).